Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Litigation
Patents
PipCast®
PTE
Webinars

Pearce IP BioBlast™: w/e 21 February 2020

by , | Feb 24, 2020

Significant biosimilar activities this week include

12 Feb 20 | Wockhardt announced divestment of assets to Dr Reddy’s, under which 62 products and a manufacturing facility will be sold for $259 million. Wockhardt stated that the funds will enable it to invest in biosimilars for the US market.

18 Feb 20 | BioPharma Reporter reported that AbbVie had outlined its defence strategy for Humira (adalimumab) competition in the US market. According to the BioPharma Reporter, AbbVIe CEO Gonzalez that explained AbbVie’s commercial US strategy will mimic the strategy employed in Europe and other markets, and stated that ex-US competition for adalimumab had been much more aggressive than AbbVie had predicted.

Print Page Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News